title: Successful desensitization to brentuximab vedotin after hypersensitivity reaction.
abstract: Monoclonal antibodies (mAb) have become the standard of care for numerous diseases. However, side effects including infusion and hypersensitivity reactions experienced by patients continue to be a limiting factor in their use. In the therapy of cancer, treatment choices are frequently limited and minimizing side effects of a life-saving or life-prolonging therapy becomes of the utmost importance. We report the successful use of a rapid desensitization protocol in a patient with NHL, treated with a novel antibody-drug conjugate, chimeric monoclonal antibody linked to the antimitotic agent monomethyl auristatin E (MMAE) Brentuximab vedotin, who had previously developed a hypersensitivity reaction.
authors.forename: Sara K
authors.initials: SK
authors.lastname: Story
authors.forename: Andrej A
authors.initials: AA
authors.lastname: Petrov
authors.forename: Larisa J
authors.initials: LJ
authors.lastname: Geskin
mesh_terms: D000079963:Brentuximab Vedotin; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects* / Q000276:immunology; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin